お知らせ • Jan 20
NovaBay Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. NovaBay Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering お知らせ • Sep 12
NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025 NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025. お知らせ • Aug 28
NovaBay Pharmaceuticals, Inc. announces special dividend, payable on September 29, 2025 NovaBay Pharmaceuticals, Inc. announced special dividend of USD 0.8000 per share payable on September 29, 2025, ex-date on September 30, 2025 and record date on September 15, 2025. お知らせ • Aug 20
NovaBay Pharmaceuticals, Inc. announced that it expects to receive $6 million in funding NovaBay Pharmaceuticals, Inc entered into a subscription agreement to issue 481,250 shares of Series D non-voting convertible preferred stock at an issue price of $8 for the proceeds of $3,850,000 and 268,750 shares of Series E non-voting convertible preferred stock at an issue price of $8 for the proceeds of $2,150,000 on August 19, 2025. The transaction involves participation of David E. Lazar as an investor.
On the same day, company closed the first tranche of Series D non-voting convertible preferred stock for the proceeds of $3,850,000. The Purchase Agreement also contemplates that Mr. Lazar will separately purchase and acquire 268,750 shares of Series E Preferred Stock as soon as practicable after the Company receives the Conversion Approval subject to shareholder approval お知らせ • Apr 02
NovaBay Pharmaceuticals, Inc. announced delayed annual 10-K filing On 04/01/2025, NovaBay Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Oct 30
RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million. RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million on October 29, 2024. Refresh’s unsolicitedoffer provides for terms that are substantially similar to the contemplated transaction with PRN, except that the Company would receive a purchase price of up to $11.5 million (compared with $9.5 million in the transaction with PRN), subject to a downside net working capital adjustment. Refresh’s unsolicitedoffer also includes Refresh providing a secured term loan to the Company in the principal amount of $2.0 million, which is expected to be repaid upon closing and deducted from the purchase price. お知らせ • Aug 02
NovaBay Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024 NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024 お知らせ • Jul 27
NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering. NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 3,200,380
Price\Range: $1.1
Security Name: Series F-1 Warrants
Security Type: Equity Warrant
Securities Offered: 3,200,380
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 3,200,380
Security Name: Series F-3 Warrants
Security Type: Equity Warrant
Securities Offered: 3,200,380
Security Name: Series F-2 Warrants
Security Type: Equity Warrant
Securities Offered: 3,200,380 お知らせ • Jul 13
Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024 NovaBay Pharmaceuticals, Inc. provided revenue guidance for the year 2024. The company expects 2024 net revenue from the Company’s eyecare products to be approximately $10 million. お知らせ • Apr 20
NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024 NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024, at 11:00 Pacific Daylight. Agenda: To elect three Class II directors nominated by our Board of Directors to hold office for a term of three years or until their respective successors are elected and qualified; to consider ratifying the appointment by our Audit Committee of WithumSmith+Brown, PC as our independent registered public accounting firm; to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of all of our Common Stock issued and outstanding; to grant authorization to our Board of Directors to determine, in its sole discretion, the specific ratio at any whole number within such share range and the timing of the Reverse Stock Split becoming effective or to abandon the Reverse Stock Split; to adjourn the Annual Meeting to establish a quorum or to permit further solicitation of proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve the proposals; and to consider other matters. お知らせ • Mar 15
New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million. New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million on March 12, 2024. The Closing is subject to certain conditions that include the Company obtaining the consent of the holders of the Company’s Original Discount Senior Secured Convertible Debentures due November 1, 2024 (the “ Convertible Notes ”) to (1) amend the Security Agreement, dated April 27, 2023, to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Convertible Notes and for DERMAdoctor to be removed as a party to such agreement and (2) terminate the Subsidiary Guarantee, dated April 27, 2023, which DERMAdoctor entered into in connection with the issuance of the Convertible Notes. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. Yaacov Brenenson of Squire Patton Boggs (US) LLP acted as legal counsel for NovaBay. お知らせ • Nov 03
NovaBay Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023 NovaBay Pharmaceuticals, Inc. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023 お知らせ • Aug 09
NovaBay Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023 NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023 お知らせ • May 19
NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023 NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023, at 11:00 Pacific Daylight. Agenda: To consider directorate elections; to ratify the appointment by the Audit Committee of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider adjourn the Annual Meeting to establish a quorum or to permit further solicitation of proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve the proposals; and to consider other matters. お知らせ • May 05
NovaBay Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023 NovaBay Pharmaceuticals, Inc. announced that they will report Q1, 2023 results After-Market on May 11, 2023 お知らせ • Feb 02
NovaBay Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 23, 2023 NovaBay Pharmaceuticals, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Mar 23, 2023